News

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel…

2 years ago

Surgalign To Collaborate with Dr. Alexander Vaccaro and Dr. Pierce Nunley to Advance HOLO™ AI Insights and its Artificial Intelligence Technologies

DEERFIELD, Ill., May 03, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on…

2 years ago

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor…

2 years ago

Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital

MIAMI, FL, May 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

2 years ago

Canary Medical Wins “Healthcare Analytics Innovation Award” in 7th Annual MedTech Breakthrough Award Program

Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and CompaniesVANCOUVER, British Columbia, May 03, 2023…

2 years ago

ReWalk Robotics Ltd. to Present at Sidoti Virtual Investor Conference on May 10

Unveils New Investor Presentation on WebsiteMARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, May 03, 2023 (GLOBE NEWSWIRE) -- ReWalk…

2 years ago

Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023

DURHAM, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in…

2 years ago

CorMedix Inc. to Participate in Two Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

2 years ago

Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation

- Transaction values Avertix at an enterprise value of $195 million- Avertix developed the Guardian™ System, the first and only…

2 years ago

Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

PALO ALTO, Calif. and MIAMI, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the…

2 years ago